Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays
Plasma Aβ<sub>1-40</sub>, Aβ<sub>1-42</sub>, and T-Tau levels are able to discriminate NC from patients with aMCI and ADD. Plasma T-Tau levels are disease-severity dependent.
Authors
- Shu‐Ping Chao (ORCID: https://orcid.org/0000-0001-8334-0251)
- Hsiu‐Chuan Wu
- Wei‐Che Lin (ORCID: https://orcid.org/0000-0002-1326-0587)
- Chaur‐Jong Hu (ORCID: https://orcid.org/0000-0002-4900-5967)
- Hsing‐Cheng Liu
- Cheng-Hsien Lu
Institutions
- Chang Gung University (TW)
- Taipei Municipal YangMing Hospital (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- Taipei City Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Journal of Alzheimer s Disease
- Published
- 2024-11-01
- DOI
- https://doi.org/10.3233/jad-240690
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.33